foxo4-dri senolytic peptide human trial 2024 2025 Targeting Senescence: A Review of Senolytics and Senomorphics in Anti-Aging Interventions Senolytic Interventions for Type 2
Senolytic Interventions for Type 2 Diabetes: Current Evidence and Future Directions The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4 DRI Nature Communications Frontiers FOXO4 DRI regulates endothelial cell senescence via the P53 signaling pathway FOXO4 DRI: Human Trial Status, Cancer Research & Senolytic Data Peptide Inhibitors Targeting FOXO4 p53 Interactions and Inducing Senescent Cancer Cell specific Apoptosis Journal of Medicinal Chemistry FOXO4 DRI regulates endothelial cell senescence via the P53 signaling pathway PMC
Pay in 4 interest-free payments of $5.35 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14





